Techniques for improving the low-frequency performance of small reverberation chambers

Small reverberation chamber low frequency performance characteristic

Estimating Emission Control Costs: A Comparison of the Approaches Implemented in the EC-EFOM-ENV and the IIASA-RAINS Models

The paper introduces two major model approaches to estimate emission control costs and develops a methodology to introduce results of energy flow optimization models (such as EFOM-ENV) into models for integrated assessment of acidification control strategies (such as the RAINS model). Based on a reference scenario for West Germany, national cost curves for reductions of SO2 and NOx emissions derived by both the EFOM-ENV and the RAINS model are compared. It is shown that -- as long as changes in the energy structure are excluded as means for reducing emissions -- results obtained from these models are comparable and the reasons for differences can be traced back to different input assumptions. However, as soon as energy conservation and fuel-substitution are utilized to reduce emissions, the simplified approach implemented in the RAINS model results in an overestimation of emission control costs

Bioacoustics and biophysical analysis of a newly described highly transparent genus of predatory katydids from the Andean cloud forest (Orthoptera: Tettigoniidae: Meconematinae: Phlugidini)

Transparency is a greatly advantageous form of camouflage, allowing species to passively avoid detection regardless of the properties of the surface which they occupy. However, it is uncommon and poorly understood in terrestrial species. In one tribe of predacious katydids (Phlugidini), transparency is paired with highly ultrasonic communication for increased predator evasion, yet little is known about the singing capabilities of these species, with only one genus of Phlugidini acoustically well described to date. Here, we describe Speculophlugis hishquten new genus and species of highly transparent crystal katydid species from the Andean cloud forest, discussing the potential use of this species for non-invasive studies of internal anatomy, and analysing its ultrasonic call. Using laser Doppler vibrometry and light microscopy techniques, we found the transparency of the cuticle around the hearing apparatus to be 85-87 % at the wavelength of the laser beam (633 nm), making S. hishquten a candidate for the highest recorded cuticle transparency of any insect. The male song has a fundamental frequency of 50 kHz, matching both the ultrasonic call range and rapid call structure of other Phlugidini species. However, the extent of ultrasonic communication and the level of transparency across the Phlugidini tribe requires more attention

Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimers Disease: 18-Month Results from the GERAS Observational Study.

BACKGROUND: While functional loss forms part of the current diagnostic criteria used to identify dementia due to Alzheimers disease, the gradual and progressive nature of the disease makes it difficult to recognize clinically relevant signposts that could be helpful in making treatment and management decisions. Having previously observed a significant relationship between stages of functional dependence (the level of assistance patients require consequent to Alzheimers disease deficits, derived from the Alzheimers Disease Cooperative Study - Activities of Daily Living Scale) and cognitive severity, we investigated whether measures of functional dependence could be utilized to identify clinical milestones of Alzheimers disease progression. OBJECTIVES: To describe the patterns of change in dependence over the course of 18 months in groups stratified according to cognitive Alzheimers disease dementia severity (determined using the Mini-Mental State Examination score) and to identify characteristics associated with patients showing worsening dependence (progressors) versus those showing no change or improvement (non-progressors). DESIGN: Analysis of longitudinal data from the GERAS study. SETTING: GERAS is an 18-month prospective, multicenter, naturalistic, observational cohort study reflecting the routine care of patients with Alzheimers disease in France, Germany, and the United Kingdom. PARTICIPANTS: 1495 community-living patients, aged ≥55 years, diagnosed with probable Alzheimers disease dementia, and their caregivers. MEASUREMENTS: Dependence levels, cognitive function, behavioral symptoms, caregiver burden, and cost were assessed at baseline and at 18 months. RESULTS: Of 971 patients having both baseline and 18-month data, 42% (408) were progressors and 563 (58%) were non-progressors. This general pattern held for all three levels of baseline Alzheimers disease dementia severity - mild (Mini-Mental State Examination score 21-26), moderate (15-20) or moderately severe/severe (<15) - with 40-45% of each group identified as progressors and 55-60% as non-progressors. No baseline differences were seen between progressors and non-progressors in cognitive scores or behavioral symptoms, although progressors had significantly shorter times since diagnosis and showed milder functional impairment. Baseline factors predictive of increasing dependence over 18 months included more severe cognitive impairment, living with others, and having multiple caregivers. A higher level of initial dependence was associated with less risk of dependence progression. Total societal costs of care also increased with greater dependence. CONCLUSIONS: In this large cohort, 42% of Alzheimers disease dementia patients at all levels of cognitive severity became more dependent within 18 months of observation while 58% did not progress. Dependence levels may be considered as meaningful interim clinical milestones that reflect Alzheimers disease-related functional deficits, although a time frame that extends beyond 18 months may be necessary to observe changes if used in clinical trials or other longitudinal studies. Recognition of predictors of greater dependence offers opportunities for intervention

Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimers Disease: Transforming Functional Scores into Levels of Dependence.

BACKGROUND: Because Alzheimers disease (AD) is characterized by a gradual decline, it can be difficult to identify distinct clinical milestones that signal disease advancement. Adapting a functional scale may be a useful way of staging disease progression that is more informative for healthcare systems. OBJECTIVES: To adapt functional scale scores into discrete levels of dependence as a way of staging disease progression that is more informative to care providers and stakeholders who rely on the functional impact of diseases to determine access to supportive services and interventions. DESIGN: Analysis of data from the GERAS study. SETTING: GERAS is an 18-month prospective, multicenter, naturalistic, observational cohort study reflecting the routine care of patients with AD in France, Germany, and the United Kingdom. PARTICIPANTS: Data were from baseline results of 1497 community-living patients, aged ≥55 years, diagnosed with probable AD and their caregivers. MEASUREMENTS: We used data from the Alzheimers Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) and mapped items onto established categories of functional dependence, validated using clinical and economic measures. Cognitive function, behavioral symptoms, caregiver burden, and cost were assessed. Based on stages of functional dependence described by the Dependence Scale, individual ADCS-ADL items were used to approximate 6 dependence levels. RESULTS: There was a significant relationship between assigned level of dependence derived from the ADCS-ADL score and cognitive severity category. As the assigned level of dependence increased, the associated clinical and economic indicators demonstrated a pattern of greater disease severity. CONCLUSIONS: This mapping provides initial support for dependence levels as appropriate interim clinical milestones that characterize the functional deficits associated with AD

The BDNF Val66Met polymorphism moderates the relationship between cognitive reserve and executive function

The concept of cognitive reserve (CR) has been proposed to account for observed discrepancies between pathology and its clinical manifestation due to underlying differences in brain structure and function. In 433 healthy older adults participating in the Tasmanian Healthy Brain Project, we investigated whether common polymorphic variations in apolipoprotein E (APOE) or brain-derived neurotrophic factor (BDNF) influenced the association between CR contributors and cognitive function in older adults. We show that BDNF Val66Met moderates the association between CR and executive function. CR accounted for 8.5% of the variance in executive function in BDNF Val homozygotes, but CR was a nonsignificant predictor in BDNF Met carriers. APOE polymorphisms were not linked to the influence of CR on cognitive function. This result implicates BDNF in having an important role in capacity for building or accessing CR

Coherence and phase techniques applied to noise diagnosis in the NASA Ames 7 times 10-foot wind tunnel no. 1

Measurements have been made of coherence and phase spectra for the acoustic field in a subsonic wind tunnel. The data are interpreted in terms of simple analytical models for propagating and diffuse noise fields, including the presence of uncorrelated noise signals. It is found that low frequency noise propagates upstream and downstream from the fan, with the noise in the test section arriving in the upstream direction. High frequency sound is generated in the test section and propagates upstream and downstream. In the low frequency range, the ratio of diffuse to propagating energy is about eight for all locations in the test section, diffuser, and settling chamber; the value of the ratio increases with frequency

Estimating Socio-Economic Status for Alzheimers Disease Trials.

INTRODUCTION: Metrics of a participants socioeconomic status (SES) are not routinely collected or standardized in clinical trials. This omission limits the ability to evaluate the generalizability of trial results and restricts clinicians from confidently interpreting the efficacy of new treatments across important sub-populations. METHODS: We adapted an SES measure of social disparity; the Hollingshead Two Factor Index of Social Position, which combines education and occupation into a single metric. We modernized the 1965 occupations to reflect the 2017 careers tabulated by the US Bureau of Labor Statistics. We currently use this adapted measure in Alzheimers Clinical Trials Consortium studies. RESULTS: We present the revised table of occupations. We found that the collection of SES data using the modified Hollingshead was feasible in a multi-site clinical trial and scores were distributed across all SES strata. DISCUSSION: The modified Hollingshead provides a standardized method for collecting SES information, enabling data aggregation, monitoring, and reporting

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.

BACKGROUND: The Anti-Amyloid in Asymptomatic Alzheimers Disease (A4) Study failed to show a treatment benefit with solanezumab, but the longitudinal consequences of elevated amyloid were observed in study participants with objective decline on the Preclinical Alzheimer Cognitive Composite (PACC) and subjective decline on the combined Cognitive Function Index (participant + study partner CFI), during the trial period. OBJECTIVES: We sought to expand on previous findings by comparing longitudinal patterns of participant and study partner CFI separately and their associations with the PACC stratified by baseline amyloid tertile over the course of the A4 Study. DESIGN: Cognitively unimpaired older adult participants and their study partners were independently administered the CFI at screen prior to amyloid PET disclosure and then at 3 subsequent visits (week 48, week 168, week 240) of the study. PACC collected at visits concurrent with CFI administration were also examined longitudinally. SETTING: The A4 Study was conducted at 67 sites in Australia, Canada, Japan, and the United States. PARTICIPANTS: 1,147 participants with elevated amyloid based on florbetapir PET were enrolled in the A4 Study and included in these analyses. 583 were on placebo and 564 were treated with solanezumab. MEASUREMENTS: The PACC was used to assess objective cognitive performance and the CFI was used to assess change in everyday cognitive functioning by the participant and their study partner independently. Amyloid level was characterized by Centiloid tertiles (<46.1 CL, 46.1 to 77.2 CL, >77.2 CL). Participants were aware of their elevated amyloid status, but not their CL tertile, or specific level of amyloid. Longitudinal correlations between participant and study partner CFI and PACC were examined at all visits where assessments were available. The impact of baseline amyloid tertile on CFI and PACC associations was also examined. RESULTS: Both participant and study partner CFI increased over the duration of the study indicating worsening cognitive functioning. Results did not differ by treatment group. The association between higher CFI and worse PACC for both for participant and study partner became progressively stronger over the course of the study. PACC had a significantly higher correlation with study partner CFI than with participant CFI by week 168. The stronger correlations between study partner CFI and PACC were driven by those in the highest amyloid tertile. CONCLUSION: Both participant and study partner report captured subtle changes in everyday cognitive functioning for participants with biomarker confirmed and disclosed preclinical AD. Moreover, study partner report was most highly aligned with cognitive decline, particularly among those with the highest amyloid load